Acadia Pharmaceuticals Inc (ACAD)

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

The Company's executive compensation policies are designed to: align executive compensation with business objectives and corporate performance; attract and retain executive officers who contribute to the Company's long-term success; reward and motivate executive officers who contribute to operating and financial performance; and link executive officer compensation and stockholder interests through the grant of long-term incentives.

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

a. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from a majority of the votes cast on the matter (excluding abstentions and broker non-votes) For, Against or Abstain No effect No effect FOR 3 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 "For" votes from a majority of the votes cast on the matter ( er NYSE rules, meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions.”.

b. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from a majority of the votes cast on the matter (excluding abstentions and broker non-votes) For, Against or Abstain No effect No effect FOR 3 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 "For" votes from a majority of the votes cast on the matter ( er NYSE rules, meaning that your broker may not vote your shares on those proposals in the absence of your voting instructions.”.

c. Approved under the standard stated in the filing — “withheld votes will have no effect For or Withhold Not applicable No effect FOR all Board nominees 2 Advisory approval of the compensation of our named executive officers "For" votes from the holders of a majority of shares present at the meeting or represented by proxy and entitled to vote on the matter For, Against or Abstain Against No effect FOR 3 Approval of the Company's 2024 Equity Incentive Plan "For" votes from a majority of votes cast on this proposal For, Against or Abstain No effect (1) No effect FOR 4 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 "For" votes from the holders of a majority of shares present at the meeting or represented by proxy and entitled to vote on the matter For, Against or Abstain Against Not applicable (2) FOR (1) If you abstain from voting on a matter requiring a majority of the votes cast, your abstention will not affect the outcome of such vote because abstentions are not considered to be votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Of the companies Acadia Pharmaceuticals Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Acadia Pharmaceuticals Inc.

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.